Literature DB >> 3081248

Interleukin 2-activated killer cells: generation in collaboration with interferon gamma and its suppression in cancer patients.

K Shiiba, R Suzuki, K Kawakami, A Ohuchi, K Kumagai.   

Abstract

The generation of lymphokine activated killer (LAK) cells by recombinant IL2 (rIL2) in collaboration with interferon gamma (IFN gamma) was examined in peripheral blood mononuclear cells (PBMC) from patients with malignant tumors of the digestive organs and breast cancer. LAK cytotoxicity could be induced by rIL2 at 10 units/ml in 10 of 12 patients and 20 of 37 using fresh autologous tumor cells and PK-1, an established solid tumor cell line as a target, respectively. Among 34 patients, in which titers of IFN gamma produced were assayed, 12 showed no IFN gamma production. All of these 12 patients had no or extremely low LAK activity, suggesting the correlation of LAK generation with the production of IFN gamma in response to rIL2. LAK induction by rIL2 in PBMC of cancer patients was almost completely inhibited by addition of anti-IFN gamma serum. Depressed LAK generation, which was accompanied by no or low levels of IFN gamma production, was partially restored by addition of exogenous recombinant IFN gamma. These results indicate that LAK induction by rIL2 in cancer patients involves the production of IFN gamma and its interaction with rIL2. The results also suggested the presence of a factor(s) suppressing LAK induction by rIL2 in the serum of cancer patients. Based on these results, the cancer patients could be divided into the following three groups. Group 1, in which the serum suppressor activity was undetectable, had the same level of LAK cytotoxicity in PBMC as healthy controls. Group 2 showed the serum suppressor factor and had the lower level of cytotoxicity in PBMC when cultivated in autologous serum (AS) compared to healthy controls. The depressed LAK induction in AS medium was restored to a normal level in culture with fetal calf serum (FCS) plus rIL2, or by addition of rIFN gamma, or high concentrations of rIL2 in AS medium. The last group (group 3), in which the serum suppressor factor was also found, had the lowest level of cytotoxicity compared to healthy controls. The LAK induction in these patients could not be restored to a normal level by culture in FCS medium, addition of exogenous rIFN gamma or high concentrations of rIL2, suggesting the possibility that the deficit of LAK generation in this group might involve the dysfunction or the lack of IL2 responder cells, in addition to the presence of a serum suppressor factor(s).

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3081248     DOI: 10.1007/bf00199859

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  24 in total

Review 1.  Lymphocyte-mediated cytotoxicity and blocking serum activity to tumor antigens.

Authors:  K E Hellström; I Hellström
Journal:  Adv Immunol       Date:  1974       Impact factor: 3.543

2.  Tumor-associated specificity of serum-mediated inhibition of lymphocyte stimulation by autochthonous human tumors.

Authors:  F Vánky; J Stjernswärd; G Klein; L Steiner; L Lindberg
Journal:  J Natl Cancer Inst       Date:  1973-07       Impact factor: 13.506

3.  Reduced lymphocyte transformation in breast cancer.

Authors:  M G Whittaker; K Rees; C G Clark
Journal:  Lancet       Date:  1971-05-01       Impact factor: 79.321

4.  Natural killer (NK) cells as a responder to interleukin 2 (IL 2). II. IL 2-induced interferon gamma production.

Authors:  K Handa; R Suzuki; H Matsui; Y Shimizu; K Kumagai
Journal:  J Immunol       Date:  1983-02       Impact factor: 5.422

5.  Natural killer (NK) cells as a responder to interleukin 2 (IL 2). I. Proliferative response and establishment of cloned cells.

Authors:  R Suzuki; K Handa; K Itoh; K Kumagai
Journal:  J Immunol       Date:  1983-02       Impact factor: 5.422

6.  Molecular cloning of human immune interferon cDNA and its expression in eukaryotic cells.

Authors:  R Devos; H Cheroutre; Y Taya; W Degrave; H Van Heuverswyn; W Fiers
Journal:  Nucleic Acids Res       Date:  1982-04-24       Impact factor: 16.971

7.  In vivo administration of purified human interleukin 2. I. Half-life and immunologic effects of the Jurkat cell line-derived interleukin 2.

Authors:  M T Lotze; L W Frana; S O Sharrow; R J Robb; S A Rosenberg
Journal:  J Immunol       Date:  1985-01       Impact factor: 5.422

8.  Cytotoxic lymphocytes induced by soluble factors derived from the medium of leukocyte cultures.

Authors:  S Kasakura
Journal:  J Immunol       Date:  1977-01       Impact factor: 5.422

9.  Lymphokine-activated killer cell phenomenon. II. Precursor phenotype is serologically distinct from peripheral T lymphocytes, memory cytotoxic thymus-derived lymphocytes, and natural killer cells.

Authors:  E A Grimm; K M Ramsey; A Mazumder; D J Wilson; J Y Djeu; S A Rosenberg
Journal:  J Exp Med       Date:  1983-03-01       Impact factor: 14.307

10.  Depressed cell-mediated immunity in patients with primary intracranial tumors. Characterization of a humoral immunosuppressive factor.

Authors:  W H Brooks; M G Netsky; D E Normansell; D A Horwitz
Journal:  J Exp Med       Date:  1972-12-01       Impact factor: 14.307

View more
  10 in total

1.  Interleukin-2-activated killer cell activity in colorectal tumor patients: evaluation of in vitro effects by prothymosin alpha1.

Authors:  K Eckert; E Grünberg; P Immenschuh; F Garbin; E D Kreuser; H R Maurer
Journal:  J Cancer Res Clin Oncol       Date:  1997       Impact factor: 4.553

2.  Phenotypic and functional analysis of lymphokine-activated killer (LAK) cell clones. Ability of CD3+, LAK cell clones to produce interferon-gamma and tumor necrosis factor upon stimulation with tumor targets.

Authors:  A S Chong; A Aleksijevic; P Scuderi; E M Hersh; W J Grimes
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

3.  Natural killer, lymphokine-activated killer and interferon-gamma producing activities of peripheral blood- and regional lymph node-mononuclear cells in 23 cases of colorectal cancer.

Authors:  H Matsunaga; Y Kuwahara; K Kusugami; K Morise; K Shimokata
Journal:  Gastroenterol Jpn       Date:  1988-10

4.  Corticosteroids inhibit the generation of lymphokine-activated killer activity in vitro.

Authors:  D W McVicar; R E Merchant; L H Merchant; H F Young
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

5.  Interleukin 2 and interferon-gamma activities of mononuclear cells from regional lymph nodes in patients with gastric cancer.

Authors:  K Kusugami; T Matsuura; T Kawase; K Ina; H Matsunaga; Y Kuwahara; T Inagaki; K Morise; K Shimokata
Journal:  Gastroenterol Jpn       Date:  1990-06

6.  Interleukin-2-inducible killer activity and its regulation by blood monocytes from autologous lymphocytes of lung cancer patients.

Authors:  S Sone; E Kunishige; F Fawzy; H Yanagawa; A Nii; K Maeda; S Atagi; Y Heike; Y Nishioka; K Mizuno
Journal:  Jpn J Cancer Res       Date:  1991-06

7.  The intensity of radiotherapy-elicited immune response is associated with esophageal cancer clearance.

Authors:  Jin-lu Ma; Long Jin; Yao-Dong Li; Chen-chen He; Xi-jing Guo; Rui Liu; Yun-Yi Yang; Su-xia Han
Journal:  J Immunol Res       Date:  2014-05-22       Impact factor: 4.818

8.  Murine tumor cells metastasizing selectively in the liver: ability to produce hepatocyte-activating cytokines interleukin-1 and/or -6.

Authors:  K Takeda; N Fujii; Y Nitta; H Sakihara; K Nakayama; H Rikiishi; K Kumagai
Journal:  Jpn J Cancer Res       Date:  1991-11

9.  Generation and characterization of lymphokine-activated killer cells against fresh human leukemia cells.

Authors:  T Tahara; R Iseki; Y Morishima; S Yokomaku; R Ohno; H Saito
Journal:  Jpn J Cancer Res       Date:  1988-03

10.  Differential activation of lymphokine-activated killer cells with different surface phenotypes by cultivation with recombinant interleukin 2 or T-cell growth factor in gastric cancer patients.

Authors:  S Koyama; T Ebihara; K Fukao; T Osuga
Journal:  Jpn J Cancer Res       Date:  1989-02
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.